In a report released today, Derek Archila from Stifel Nicolaus assigned a Buy rating to Esperion (NASDAQ: ESPR). The company’s shares opened today at $40.21, close to its 52-week low of $33.06.
Archila said:
“We believe ESPR’s Study 2 data for bempedoic acid (BPA) should get investors more comfortable around BPA’s safety profile and, we think, put to rest a key stock controversy surrounding the imbalance in unrelated drug fatalities seen in the study 1 results from May 2018.”
According to TipRanks.com, Archila is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -10.3% and a 28.6% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Rhythm Pharmaceuticals Inc, and Pacira Pharmaceuticals.
Currently, the analyst consensus on Esperion is a Strong Buy with an average price target of $78.60, representing a 95.5% upside. In a report issued on October 16, BTIG also initiated coverage with a Buy rating on the stock with a $82 price target.
.
See today’s analyst top recommended stocks >>
Based on Esperion’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $45.73 million. In comparison, last year the company had a GAAP net loss of $45.22 million.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ESPR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Esperion Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).
